reason report
confid fy guid reflect assur recov
bottom line remain outperform agil given well
diversifi posit across healthcar growth end-market
pharma dx genom lead posit chemic
 end-market us agil remain accur len
view china coronaviru impact recoveri given strong legaci
posit rev manag understand local
market overal landscap china agil came us
street highlight impact coronaviru
compani maintain full yr guid remain confid
recov
believ provid relief investor concern pace
recoveri china revenu growth driver nasd oligo busi
uptak cell analysi busi strength biopharma remain
intact could allow upsid given stabil china busi
remain outperform agil rais pt move
china impact quantifi agil remain confid
recov revenu agil post total revenu
driven core growth slightli street expect
strong org growth crosslab off-set
weak lsag larg due impact coronaviru
management indic china trend ahead plan msd growth prior
viru impact end grow first
half management expect impact busi
viru impli increment importantli management
remain confid major busi lost delay
recaptur later management remain confid mid-singl
digit perform region food biz show sign
nasd manufactur ramp track cell analysi biz continu
strong nasd frederick co facil manufactur ramp
progress expect although full capac yet contribut
partial dxg agil overal org growth recal one
two lead supplier market provid raw materi gene
therapi manufactur agil current deliv close
oligo busi forecast busi reach end
half growth bake current guid provid
upsid opportun view nasd becom
materi contributor agil also built strong cell analysi offer
seahors biotek luxcel busi annual
grew
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu us million ep exclud item amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
guid left unchang back-half weight management
maintain guidanc organ revenue growth
rang guidanc affect
coronaviru revenu impact management expect fulli recov
sale within year howev protract recoveri china
could impact much recaptur modestli lower
organ revenue growth reflect increas
conservat ep larg unchang lower revenu off-set
favor tax rate updat
rate agil share outperform price target view agil
posit believ compani hold lead posit environment chemic
food test market around world maintain well-diversifi posit across
healthcar biopharma life scienc tool lst diagnost compani also repres
margin expans opportun medium longer term spin-off keysight
electron manag busi becom pure-play life scienc tool lst compani
agil continu deliv improv adjust oper margin despit growth initi
believ achiev exceed longer term leadership
ceo mcmullen agil compet aggress multipl market deliv solid growth
biopharma sale maintain either posit across
end-market includ food environment chemical/energi emerg market post
solid growth agil posit capit given sizabl exposur geographi
intuvo product cycl could repres opportun current under-
appreci view agil repres compani develop core root
industri chemic electron market year transform life
scienc tool technolog leader diversifi access lead end-market
agil share current trade ev/ebitda under-valued view
compar life scienc tool peer group
averag believ ev/ebitda valuat provid best measur
agil valu price target expect agil trade slight premium
averag lst group ev/ebitda multipl result appli
ev/ebitda multipl ebitda estim arriv pt
primari risk price target includ
biopharma declin pose greatest risk agil margin expans plan declin
biopharma fund could highli impact agil revenu given revenu lever
biopharma industri believ gener biopharma price risk mute given
elect outcom howev impact regulatori chang could see
biopharma compani becom cautiou spend could impact capit
equip purchas includ agil slowdown biopharma fund would
result downsid risk estim valuat biomolecul forecast ramp
drug market mid-teen believ prolifer drive
use agil mass spectromet character molecul pronounc
slowdown biopharma core growth requir margin expans would
slowdown global budget research could pose downsid risk forecast tighten
budget govern academ fund could result lower revenu rel
estim agil much academ government exposur
competitor nevertheless slowdown academ spend could
headwind plan margin expans assum expect core growth furthermor
restrict global budget could result shift focu strategi growth could
increas oper risk declin government spend could risk downsid
forecast growth nih spend flat low-single-digit
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit
risk could also impact agil strategi creat higher barrier entri exist futur
market agil oper numer intern market includ china middl east
europ macroeconom impact chines market could lead declin compani
revenu regul chines polici could also caus restrict oper lead
lower activ china question remain china concern detail
headwind could emerg polici risk
continu volatil energi chemic sector could impact growth agil
consider exposur revenu chemic energi industri agil expect
recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
dollar million except per share data
good sold
sg sale
 sale
oper expens sale
compani report svb leerink estim
